NYSEA:ATCH 9 October 2025

AtlasClear (ATCH) Stock Skyrockets 50% on $20M Financing – Fintech Underdog Poised to Soar?

AtlasClear (ATCH) closed at $0.36 on Oct. 8, 2025, with a 52-week range of $0.14–$26.94 and short interest near 28%. The company announced a $20M financing on Oct. 9, led by Funicular Funds, after closing a $5M round in September. AtlasClear reported FY2025 revenues of about $10–11M and negative margins, following an 83% reduction in debt. It plans to acquire Commercial Bancorp of Wyoming.

9 October 2025

Fintech·NYSEA:ATCH·Stock Market

Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).